

Adverse cardiovascular complications following prescription of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) inhibitors

Jiandong Zhou *¹, Gary Tse MD FRCP FACC *^{2,3}, Xiansong Wang MPhil⁴, Ishan Lakhani³, Sharen Lee³, Lei Yang MD PhD², Tong Liu MD PhD², Yunlong Xia MD PhD FACC⁵, Esther W Chan PhD⁶, Ian Chi Kei Wong PhD⁶, William KK Wu PhD FRCPath #⁴, Qingpeng Zhang PhD #¹

¹ School of Data Science, City University of Hong Kong, Hong Kong, China

² Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

³ Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong, China

⁴ Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

⁵ Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, China

⁶ Department of Pharmacology and Pharmacy, University of Hong Kong, Pokfulam, Hong Kong, China

* joint first author

Correspondence to:

Prof. William KK Wu PhD FRCPath FRCP

Li Ka Shing Institute of Health Sciences, Hong Kong, China

Email: wukakei@cuhk.edu.hk

Prof. Qingpeng Zhang PhD

School of Data Science, City University of Hong Kong,

Hong Kong, China

Email: qingpeng.zhang@cityu.edu.hk

ABSTRACT

Background: Programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are a major class of immune checkpoint inhibitors that are increasingly used for cancer treatment. However, their use is associated with adverse cardiovascular events. We examined the incidence of new-onset cardiac complications in patients receiving PD-1 or PD-L1 inhibitors.

Methods: Patients receiving PD-1 or PD-L1 inhibitors since their launch up to 31st December 2019 at the Hospital Authority of Hong Kong, without pre-existing cardiac complications were included. The primary outcome was a composite of incident heart failure, acute myocardial infarction (AMI), atrial fibrillation (AF) or atrial flutter with the last follow-up date of 31st August 2020.

Results: A total of 1959 patients were included. Over a median follow-up of 136 days (IQR: 42-279), 320 (16.3%) patients met the primary outcome (heart failure: n=244, AMI: n=38, AF: n=54, atrial flutter: n=6) after PD-1/PD-L1 treatment. Univariate Cox regression showed that age, respiratory diseases, gastrointestinal diseases, a shorter readmission interval and total number of hospitalizations before PD-1/PD-L1 inhibitor prescription, PD-L1 inhibitor use, hyponatraemia, and reduced triglyceride levels were significant predictors of the primary outcome. On multivariate adjustment, older age, a shorter average readmission interval, and a higher number of hospital admissions remained significant predictors. Patients who developed cardiovascular complications had a shorter average readmission interval and a higher number of hospitalizations after PD-1/PD-L1 treatment.

Conclusions: Cardiovascular complications are found in 16% of patients receiving PD-1 or PD-L1 inhibitors and are associated with more healthcare utilization.

Introduction

The programmed death 1 (PD-1)/programmed death 1 ligand (PD-L1) pathway is one of the major immune checkpoints for mitigating the immune response to prevent autoimmunity. However, cancer cells often devise strategies to hijack these mechanisms to evade anti-tumor immunity. In this regard, inhibitors of PD-1 (e.g. pembrolizumab, nivolumab, cemiplimab) and PD-L1 (e.g. atezolizumab, avelumab, durvalumab) have shown clinical efficacies against different types of solid tumors, including melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma and bladder cancer. Pembrolizumab is also the first agent to receive a “pan-cancer” approval by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic solid tumors that have high microsatellite instability or mismatch repair deficiency.

Despite their efficacies in clinical oncology, immune-related adverse events associated with the use of immune checkpoint inhibitors (ICIs) are now increasingly recognized. Such adverse events include colitis, hepatitis, adrenocorticotrophic hormone insufficiency, hypothyroidism, type 1 diabetes, and acute kidney injury. To this end, cardiovascular complications are estimated to constitute approximately 2% of ICI inhibitor-related adverse drug reactions¹. The commonest is myocarditis, but other cardiovascular abnormalities reported are left ventricular dysfunction, acute myocardial infarction (AMI), cardiac arrhythmias and heart failure (HF)². These cardiovascular complications typically present with clinical heterogeneity, and in turn account for the high morbidity and mortality rates observed in such patient cohorts. Whilst cardiotoxicity is being documented with an increasing frequency, their cumulative incidence rates remain largely unexplored. In this territory-wide study, we examined the

incidence of cardiovascular events of incident heart failure, AMI, atrial fibrillation (AF) or atrial flutter in cancer patients receiving PD-1 or PD-L1 inhibitors.

Methods

Study Population

This study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee and The Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. Patient data were obtained using the electronic health record database, which is connected to the territory-wide Clinical Data Analysis and Reporting System (CDARS). The system is an integrative centralized platform that permits the extraction of clinical data for analysis and reporting. The system attributes each patient a unique reference identification number, allowing for the retrieval of comprehensive medical records, including disease diagnoses, clinical comorbidities, laboratory parameters and operative procedures. Patients or the public were not involved in any aspect of this study.

Patient Data

The following clinical data were extracted: patient characteristics, including demographic details of baseline age and gender, and specific pre-existing comorbidities before drug prescriptions, laboratory examinations (including complete blood counts, biochemical tests, diabetes mellitus tests) were extracted. Comorbidities from January 1st, 2013 to December 31st, 2019 were extracted, and categorized into cardiovascular, respiratory, kidney, diabetes mellitus, endocrine, hypertension, gastrointestinal, stroke/transient ischemic attack (TIA) and HF. The

International Classification of Disease, Ninth Edition (ICD-9) codes that were used to extract the specific comorbidities and outcomes are included in **Supplementary Materials**. The overall dosage and accumulative duration for patients with new-onset cardiac complications are reported.

Primary outcomes on follow-up

The primary outcome was a composite of incident heart failure, AMI, AF or atrial flutter. The follow-up period was defined as the first PD-1/PD-L1 prescription date until the primary endpoint or death occurred, or until the end date of December 31st, 2019, whichever was earlier.

Statistical analysis

Continuous variables were presented as median (95% confidence interval [CI] or interquartile range [IQR]) and categorical variables were presented as count (%). The Mann-Whitney U test was used to compare continuous variables. The χ^2 test with Yates' correction was used for 2×2 contingency data, and Pearson's χ^2 test was used for contingency data for variables with more than two categories. To identify the important predictors associated with new-onset cardiac complications of patients after PD-1/PD-L1 treatment, univariate Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. The identified significant univariate predictors were used as the input into the multivariate Cox regression model. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses (including logistic regression) were performed using RStudio software (Version: 1.1.456) and Python (Version: 3.6).

Results

Baseline characteristics

Initially, 2,426 cancer patients receiving PD-1/PD-L1 inhibitors were identified (**Figure 1**). Subsequently, those with prior cardiac complications (n=467, all HF) before PD-1/PD-L1 inhibitor treatment were excluded. Their baseline characteristics are shown in **Table 1**. Over a median follow-up of 136 days (IQR: 42-279) from initial PD-1/PD-L1 treatment, 320 (16.3%) met the primary outcome of developing new-onset cardiac complications (244 with HF, 38 with AMI, 54 with atrial fibrillation, 6 with atrial flutter; **Figure 2**). At the end of study period, 286 (89.4%) of those with new onset cardiac complications died over a median follow-up of 178 days (IQR: 73-349 days). In contrast, for those without the development of cardiac complications, 1,034 out of 1,639 patients (63.1%) died.

Compared to those without cardiovascular complications, those who developed such complications had higher frequency of respiratory diseases (65.9% v.s. 55.3%, p value=0.0016), had a longer length of stay (median: 30 days, 95% CI: 14.5-54.0, max: 241.0 v.s. median: 23 days, IQR: 11.0-44.0, max: 479.0, p value<0.0001), and higher overall PD-L1 dosage (median: 6.0×10^4 mg, IQR: 2.4-13.2, max: ;279.6 v.s. median: 4.8×10^4 mg, IQR: 2.4-10.8, amx: 239.9), lower vitamin B12 level (median: 267.5 pmol/L, IQR: 239.77-339.0, max: 472.0 v.s. 319.0 pmol/L, IQR: 243.5-583.32, max: 1475.6, p value<0.0001), higher folate level (median: 25.9 ng/mL, IQR: 14.1-33.6, max: 53.2 v.s. 19.32 ng/mL, IQR: 14.9-26.1, max: 45.32, p value<0.0001) and higher ferritin level (median: 1146.1 pmol/L, IQR: 693.5-3257.03, max: 5824.2 v.s. 1037.1 pmol/L, IQR: 278.3-2422.0, max: 13000.0, p value=0.0065).

Predictors of cardiac complications

Univariate Cox proportional hazard analysis identified the significant predictors of the primary outcome (**Table 2**). These were older age at initial PD-1/PD-L1 treatment (HR: 1.02, 95%

CI: [1.01,1.03], $p < 0.0001$); baseline respiratory diseases (HR: 1.02, 95% CI: [1.01,1.03], $p = 0.0039$), endocrine diseases (HR: 1.02, 95% CI: [1.00,1.03], $p = 0.043$), gastrointestinal diseases (HR: 1.02, 95% CI: [1.01,1.03], $p < 0.0001$); higher total number of hospitalizations (HR: 1.02, 95% CI: [1.01,1.04], $p < 0.0001$) before drug treatment; medication prescription of PD-L1 drugs (HR: 1.21, 95% CI: [1.09,1.62], $p < 0.0001$), shorter overall PD-1 treatment duration (HR: 0.998, 95% CI: [0.997,1.000], $p = 0.008$); lower sodium level (HR: 0.97, 95% CI: [0.95,1.00], $p = 0.0289$), lower triglyceride level (HR: 0.78, 95% CI: [0.61,0.99], $p = 0.0406$).

Multivariate Cox regression showed that older age at PD-1/PD-L1 treatment (HR: 1.02, 95% CI: [1.01,1.03], $p < 0.0001$), shorter average readmission interval (HR: 0.99, 95% CI: [0.98,0.996], $p = 0.0014$) and more total episode number (HR: 1.02, 95% CI: [1.01,1.03], $p < 0.0001$) were significant in predicting cardiac complication development after drug treatment (**Table 3**).

Healthcare utilization before and after treatment with PD-1/PD-L1 inhibitors

Further, we compared the hospitalization characteristics before and after PD-1/PD-L1 treatment in patients with cardiovascular complications (**Table 4**). Patients who developed HF had a shorter average readmission interval (23.7 days, IQR: 14.1-39.4, max: 1045.7 v.s. median: 69.2, IQR: 19.38-260.85, max: 5669.0, $p < 0.0001$), a higher number of hospitalizations (median: 10.5, IQR: 6.0-17.0, max: 77.0 v.s. median: 7.0, IQR: 3.0-12.5, max: 32.0, $p < 0.0001$) and a longer overall hospitalization (median: 31 days, IQR: 16.0-54.5, max: 190 v.s. median: 17 days (7.0-35.0), max: 343, $p < 0.0001$) after PD-1/PD-L1 treatment. Similar patterns were observed for patients who developed PD-1/PD-L1 inhibitor-associated AMI, AF or atrial flutter.

Discussion

The main findings are that: i) the incidence of cardiovascular complications after PD-1 or PD-L1 inhibitor use was 16% in this territory-wide cohort of Chinese patients from Hong Kong, ii) multivariate Cox regression showed older age, a shorter average readmission interval and a higher number of hospital admissions were significant predictors of cardiovascular complications and iii) patients who developed cardiovascular complications had shorter average readmission interval and higher number of hospitalizations after treatment with PD-1/PD-L1 inhibitors.

Cardiac involvement in PD1 or PD-L1 inhibitors is variable, and can potentially affect the conduction system, myocardium or pericardium ³. Thus, heart block ⁴, Takotsubo cardiomyopathy ⁵, myocarditis ^{6, 7} and pericarditis ⁸ have been reported. A meta-analysis performed in 2018 found that “anti-PD-1/PD-L1-related fatalities were often from pneumonitis (333 [35%]), hepatitis (115 [22%]), and neurotoxic effects (50 [15%]). Combination PD-1/CTLA-4 deaths were frequently from colitis (32 [37%]) and myocarditis (22 [25%])” ⁹. In an analysis of the World Health Organization global database of adverse drug reactions conducted in 2019, 2.1% of 106,025 patients receiving PD-1 or PD-L1 inhibitors had cardiovascular complications ¹. However, previous studies have largely been limited to case reports ^{4, 10}, case series ¹¹ or single-center studies ¹² or small registries ^{13, 14}. In this territory-wide study from Hong Kong, we found that cardiovascular complications occurred in 16% of all patients receiving PD1 or PD-L1 inhibitors. Of these, the commonest is HF. Previously, acute HF has been described in the context of myocarditis ¹⁵, but HF without myocarditis has also been reported ¹⁶. Our study also identified cases of AMI following the initiation of PD-1/PD-L1 inhibitor therapy. Such findings would be in keeping with coronary toxicity that has been reported in the context of PD-1 inhibitor therapy ¹³.

Interestingly, our study did not identify any patients with myocarditis after treatment with PD-1 or PD-L1 inhibitors. Moreover, within the excluded patients with prior cardiovascular complications, none developed subsequent myocarditis. In 964 patients attending Massachusetts General Hospital, the incidence of myocarditis was 1.1% (n = 35)¹⁴. In this cohort, myocarditis was more frequently observed in patients with pre-existing cardiovascular comorbidities. Nevertheless, another study using the VigiBase database found 101 cases of severe myocarditis, of which 75% of the myocarditis cases did not have pre-existing cardiovascular disease¹⁷. A single-center study of 283 patients from China found only 3 cases (1.1%) of myocarditis, with variable presentations such as palpitations, dyspnea, and fatigue, or asymptomatic with incidental finding of grade 3 atrioventricular block and premature ventricular complexes on the electrocardiogram¹². In a pooled, retrospective review of three trials including 448 patients with advanced melanoma receiving PD-1/PD-L1 inhibitor therapy, no cases of myocarditis were identified¹⁸. In association with myocarditis, different investigators have reported the presence of conduction abnormalities in the form of atrioventricular block^{4, 11, 12, 19}.

Conclusions

Cardiovascular complications are found in 16% of patients receiving PD-1 or PD-L1 inhibitors and are associated with more healthcare utilization.

Consent for publication

N/A.

Availability of data and material

Data availability upon request to the corresponding author.

Competing interests

None.

Funding

None.

Authors' contributions

JZ, GT: data analysis, data interpretation, statistical analysis, manuscript drafting, critical revision of manuscript

XW, IL, SL, LY, TL, YX: data interpretation, manuscript drafting

EWC, ICKW: project planning, data acquisition, data interpretation, critical revision of manuscript

WTW, QZ: study conception, study supervision, project planning, data interpretation, statistical analysis, manuscript drafting, critical revision of manuscript

Acknowledgements

None.

References

1. Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. *Chronic Dis Transl Med*. 2019;5:6-14
2. Muller OJ, Spehlmann ME, Frey N. Cardio-toxicity of checkpoint inhibitors. *J Thorac Dis*. 2018;10:S4400-S4404
3. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol*. 2018;19:e447-e458
4. Khan A, Riaz S, Carhart R, Jr. Pembrolizumab-induced mobitz type 2 second-degree atrioventricular block. *Case Rep Cardiol*. 2020;2020:8428210
5. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: A case of takotsubo-like syndrome. *J Immunother Cancer*. 2015;3:4
6. Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM. Smoldering myocarditis following immune checkpoint blockade. *J Immunother Cancer*. 2017;5:91
7. Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C. Drug-induced myocarditis after nivolumab treatment in a patient with pd1- negative squamous cell carcinoma of the lung. *Lung Cancer*. 2016;99:117-119
8. de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. *J Immunother*. 2018;41:329-331
9. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. *JAMA Oncol*. 2018;4:1721-1728
10. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering

- RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Korálnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Jr., Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. *N Engl J Med*. 2016;375:1749-1755
11. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with ctla4 and pd1 blocking immunotherapy. *J Immunother Cancer*. 2016;4:50
 12. Wang F, Sun X, Qin S, Hua H, Liu X, Yang L, Yang M. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in china. *Chin Clin Oncol*. 2020;9:16
 13. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S. Coronary toxicities of anti-pd-1 and anti-pd-l1 immunotherapies: A case report and review of the literature and international registries. *Target Oncol*. 2018;13:509-515
 14. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol*. 2018;71:1755-1764
 15. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. *J Immunother Cancer*. 2015;3:11
 16. Chauhan A, Burkeen G, Houranieh J, Arnold S, Anthony L. Immune checkpoint-associated cardiotoxicity: Case report with systematic review of literature. *Ann Oncol*. 2017;28:2034-2038
 17. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet*. 2018;391:933
 18. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbe C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W,

- Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhoré R, Jiang J, Hodi FS, Wolchok JD. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *J Clin Oncol*. 2017;35:3815-3822
19. Lopez EM, Dunn S, Mazimba S. Malignant arrhythmias in autoimmune myocarditis secondary to immune checkpoint blockade treatment. *Journal of the American College of Cardiology*. 2018;71:A2375

Table 1. Clinical characteristics of patients who developed cardiac complications after PD-1/PD-L1 inhibitor use

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

	Cardiac complications (N=320, mortality: 286, 89.37%) Median(IQR);Max;N or Count (%)	No cardiac complications (N=1639, mortality: 1034, 63.08%) Median(IQR);Max;N or Count (%)	P value
Demographics			
Age at initial PD1/PD-L1 treatment, years	64.5(56.1-73.1);94.9;n=320	61.9(53.3-69.9);93.9;n=1639	0.0676
Male gender	219(68.43%)	1122(68.45%)	0.2349
Past comorbidities			
Respiratory	211(65.93%)	907(55.33%)	0.0016**
Kidney	55(17.18%)	237(14.46%)	0.0706
Diabetes mellitus	30(9.37%)	126(7.68%)	0.6372
Endocrine	76(23.75%)	472(28.79%)	0.9488
Hypertension	49(15.31%)	207(12.62%)	0.0696
Gastrointestinal	230(71.87%)	1182(72.11%)	0.3576
Stroke/TIA	17(5.31%)	63(3.84%)	0.1287
Healthcare utilization before PD1/PD-L1 treatment			
Average readmission interval, days	24.2(14.0-42.1);1045.7;n=312	25.2(16.2-49.4);3919.0;n=1564	0.6976
Total number of hospitalizations	10.0(5.5-17.0);77.0;n=312	7.0(5.0-16.0);166.0;n=1564	0.2161
Total in-hospital length of stay, days	30.0(14.5-54.0);241.0;n=312	23.0(11.0-44.0);479.0;n=1564	<0.0001***
Medications			
PD-L1 use	53(16.56%)	230(14.03%)	0.0728
Total PD-L1 dose amount, x10 ⁴ mg	6.0 (2.4-13.2);279.6;n=48	4.8(2.4-10.8);239.9;n=212	0.0439*
Total PD-L1 duration, days	4.0(2.0-11.0);168.0;n=48	4.0(2.0-10.0);619.0;n=212	0.2016
PD1 use	276(86.25%)	1441(87.91%)	0.8130
Total PD1 dose amount, x10 ⁴ mg	0.8 (0.4-1.8);80.5;n=233	0.7(0.3-1.8);138.4;n=1221	0.5131
Total PD1 duration, days	6.0(3.0-12.0);1512.0;n=233	6.0(2.0-19.0);1934.0;n=1221	0.6317
Complete blood count tests			
Mean corpuscular volume, fL	89.55(85.8-93.3);108.1;n=320	88.9(85.0-92.7);114.3;n=1633	0.8127
Basophil, x10 ⁹ /L	0.02(0.01-0.04);0.54;n=296	0.02(0.01-0.04);0.6;n=1489	0.9198

Eosinophil, x10 ⁹ /L	0.12(0.07-0.22);1.68;n=320	0.1(0.05-0.2);6.3;n=1632	0.5337
Lymphocyte, x10 ⁹ /L	1.5(1.03-1.9);14.01;n=320	1.4(1.0-1.84);15.38;n=1633	0.5945
Metamyelocyte, x10 ⁹ /L	0.12(0.06-0.35);3.83;n=37	0.16(0.06-0.46);75.12;n=188	0.8667
Monocyte, x10 ⁹ /L	0.5(0.4-0.7);2.74;n=320	0.48(0.32-0.67);4.2;n=1633	0.3653
Neutrophil, x10 ⁹ /L	4.4(3.12-5.97);31.9;n=320	4.3(3.0-6.2);27.8;n=1633	0.9584
White blood count, x10 ⁹ /L	6.6(5.15-8.7);33.8;n=320	6.55(5.0-8.83);188.2;n=1633	0.2060
Mean cell haemoglobin, pg	31.4(29.3-33.3);37.4;n=320	31.0(29.0-33.1);40.6;n=1633	0.5947
Myelocyte, x10 ⁹ /L	0.17(0.1-0.46);6.13;n=50	0.18(0.08-0.55);50.08;n=278	0.4337
Platelet, x10 ⁹ /L	236.5(184.0-303.5);654.0;n=320	237.0(176.0-300.0);794.0;n=1633	0.3980
Reticulocyte, x10 ⁹ /L	66.2(26.1-77.1);97.4;n=13	62.7(42.96-90.05);1885.68;n=86	0.7582
Red blood count, x10 ¹² /L	4.41(4.0-4.8);6.6;n=320	4.45(3.97-4.81);7.47;n=1633	0.5546
Hematocrit, L/L	0.39(0.35-0.4);0.54;n=303	0.39(0.35-0.42);0.56;n=1592	0.7010
Liver and renal function tests			
Potassium, mmol/L	4.1(3.83-4.4);5.6;n=318	4.1(3.8-4.4);6.1;n=1623	0.1543
Urate, mmol/L	0.31(0.25-0.41);1.2747;n=96	0.3(0.24-0.4);1.115;n=531	0.5885
Albumin, g/L	40.7(36.0-43.0);54.0;n=318	40.0(36.0-43.0);53.5;n=1621	0.6026
Na/Sodium, mmol/L	140.0(137.0-141.4);147.7;n=318	140(137.7-141.04);155;n=1623	0.2352
Urea, mmol/L	5.2(4.1-6.5);29.7;n=317	5.1(4.2-6.32);42.1;n=1620	0.4444
Protein, g/L	73.8(69.5-78.0);95.0;n=308	74.0(69.0-78.0);94.0;n=1545	0.4407
Creatinine, μmol/L	74.5(62.7-92.0);423.0;n=320	75.0(63.0-91.0);1324.0;n=1632	0.0652
Alkaline phosphatase, U/L	81.4(64.2-109.0);1021.0;n=318	80.0(64.0-108.0);2167.0;n=1623	0.1804
Aspartate transaminase, U/L	29.0(21.0-47.1);650.0;n=210	29.0(21.0-48.0);1809.0;n=1115	0.3552
Alanine transaminase, U/L	20.4(15.0-34.0);904.0;n=301	23.0(16.0-39.0);817.4;n=1573	0.8647
Bilirubin, μmol/L	8.9(6.0-13.0);261.0;n=318	8.8(6.0-13.0);517.0;n=1623	0.3986
Lipid, iron and other tests			
Triglyceride, mmol/L	1.0(0.8-1.3);5.5;n=110	1.15(0.82-1.7);11.01;n=488	0.8900
LDL, mmol/L	2.4(2.0-3.1);6.1136;n=109	2.52(1.98-3.23);6.0991;n=474	0.9940
HDL, mmol/L	1.3(1.1-1.59);2.4;n=109	1.26(1.1-1.56);2.8;n=484	0.2398
Cholesterol, mmol/L	4.3(3.8-5.04);8.0;n=110	4.6(3.8-5.3);8.41;n=489	0.4218

Calcium, mmol/L	2.32(2.22-2.39);2.8;n=185	2.32(2.2-2.4);3.66;n=896	0.3269
TIBC, L	39.8(33.4-50.44);72.1;n=13	40.2(32.4-45.2);85.21;n=90	0.7427
Vitamin B12, pmol/L	267.5(239.77-339.0);472.0;n=6	319.0(243.5-583.32);1475.6;n=43	<0.0001***
Folate, ng/mL	25.94(14.1-33.6);53.2;n=8	19.32(14.9-26.1043);45.32;n=61	<0.0001***
Ferritin, pmol/L	1146.1(693.5-3257.03);5824.2;n=12	1037.1(278.3-2422.0);13000.0;n=74	0.0065**
Phosphate, mmol/L	1.05(0.93-1.12);1.65;n=159	1.06(0.94-1.19);3.043;n=789	0.7579
Diabetes mellitus and clotting function tests			
HbA1c, g/dL	12.95(11.6-14.2);19.2;n=320	12.9(11.4-14.1);18.7;n=1633	0.7238
Fast glucose, mmol/L	5.6(5.04-7.0);25.64;n=294	5.64(5.1-6.76);35.09;n=1474	0.3702
High sensitive troponin-I, ng/L	6.03(0.03-17.44);70218.6;n=232	4.6(0.03-12.4);3254.6;n=909	0.5541
Lactate dehydrogenase, U/L	232(192.5-307.5);5055.0;n=247	231(188-306.5);6295;n=1184	0.9965
APTT, second	30.0(27.6-33.0);42.6;n=118	29.9(27.8-33.05);120.0;n=576	0.6419
Prothrombin Time/INR, second	12.5(11.8-13.45);28.4;n=108	12.6(11.8-13.4);320.0;n=542	0.5625

Table 2. Significant univariate predictors of cardiac complications

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

	Cardiac complications HR [95% CI]	P value
Demographics		
Age at initial PD-1/PD-L1 treatment, years	1.02[1.01,1.03]	<0.0001***
Male gender	1.01[0.79,1.27]	0.961
Past comorbidities		
Respiratory	1.02[1.01,1.03]	0.004**
Kidney	1.01[0.99,1.03]	0.439
Diabetes mellitus	1.01[0.97,1.05]	0.654
Endocrine	1.02[1.00,1.03]	0.043*
Hypertension	1.01[0.99,1.04]	0.306
Gastrointestinal	1.02[1.01,1.03]	<0.0001***
Stroke/TIA	1.03[0.99,1.08]	0.134
Healthcare utilization before treatment		
Average readmission interval, days	0.998[0.996,1.000]	0.0289*
Total number of hospitalizations	1.02[1.01,1.04]	<0.0001***
Total in-hospital length of stay, days	1.01[1.00,1.03]	0.257
Medications		
PD-L1 inhibitor use	1.21[1.09,1.62]	<0.0001***
Total PD-L1 inhibitor dose amount, $\times 10^4$ mg	1.001[1.000,1.003]	0.403
Total PD-L1 inhibitor duration, days	0.996[0.985,1.007]	0.444
PD-1 inhibitor use	0.80[0.58,1.10]	0.161
Total PD-1 inhibitor dose amount, $\times 10^4$ mg	1.001[1.000,1.003]	0.374
Total PD1 inhibitor duration, days	0.998[0.997,1.000]	0.008**
Complete blood count tests		
Mean corpuscular volume, fL	1.01[1.00,1.03]	0.056
Basophil, $\times 10^9/L$	1.21[0.05,28.82]	0.907
Eosinophil, $\times 10^9/L$	0.83[0.55,1.27]	0.399
Lymphocyte, $\times 10^9/L$	1.08[0.98,1.20]	0.123
Metamyelocyte, $\times 10^9/L$	0.77[0.46,1.28]	0.314
Monocyte, $\times 10^9/L$	1.23[0.89,1.70]	0.204
Neutrophil, $\times 10^9/L$	1.02[0.98,1.05]	0.364
White blood count, $\times 10^9/L$	1.01[1.00,1.03]	0.115
Mean cell haemoglobin, pg	1.01[0.98,1.05]	0.474
Myelocyte, $\times 10^9/L$	0.92[0.73,1.15]	0.451
Platelet, $\times 10^9/L$	1.00[1.00,1.00]	0.389
Reticulocyte, $\times 10^9/L$	0.98[0.96,1.01]	0.152
Red blood count, $\times 10^{12}/L$	0.93[0.79,1.09]	0.348
Hematocrit, L/L	1.06[0.13,8.29]	0.958

Liver and renal function tests		
Potassium, mmol/L	1.01[0.79,1.30]	0.917
Urate, mmol/L	3.55[0.79,15.98]	0.099
Albumin, g/L	0.98[0.96,1.00]	0.070
Sodium, mmol/L	0.97[0.95,1.00]	0.029*
Urea, mmol/L	1.02[0.98,1.06]	0.333
Protein, g/L	0.998[0.989,1.007]	0.636
Creatinine, μ mol/L	1.000[0.998,1.002]	0.812
Alkaline phosphatase, U/L	1.001[0.999,1.002]	0.766
Aspartate transaminase, U/L	1.000[0.998,1.001]	0.869
Alanine transaminase, U/L	1.001[0.998,1.002]	0.891
Bilirubin, μ mol/L	1.001[0.996,1.006]	0.754

Lipid, iron and other tests		
Triglyceride, mmol/L	0.78[0.61,0.99]	0.041*
LDL, mmol/L	0.86[0.70,1.07]	0.180
HDL, mmol/L	1.12[0.71,1.78]	0.618
Cholesterol, mmol/L	0.85[0.70,1.01]	0.071
Calcium, mmol/L	0.51[0.18,1.46]	0.210
TIBC, L	1.01[0.96,1.05]	0.802
VitaminB12, pmol/L	1.00[0.99,1.00]	0.178
Folate, ng/mL	1.04[0.98,1.10]	0.163
Ferritin, pmol/L	1.01[1.00,1.02]	0.583
Phosphate, mmol/L	0.72[0.34,1.53]	0.395

Diabetes mellitus and clotting function tests		
HbA1c, g/dL	0.99[0.96,1.03]	0.585
Fast glucose, mmol/L	1.00[0.95,1.05]	0.929
High sensitive troponin-I, ng/L	1.002[1.001,1.004]	0.153
Lactate dehydrogenase, U/L	1.003[1.002,1.006]	0.095
APTT, second	0.99[0.95,1.04]	0.686
Prothrombin Time/INR, second	1.01[0.99,1.02]	0.633

Table 3. Multivariate predictors of cardiac complications

* for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

	Cardiac complications HR [95% CI]	P value
Age at initial PD-1/PD-L1 treatment, years	1.02[1.01,1.03]	<0.0001***
Respiratory	1.2[0.8,1.9]	0.421
Gastrointestinal	1.2[0.7,2.0]	0.336
Average readmission interval, days	0.99[0.98,0.996]	0.001**
Total number of hospitalizations	1.02[1.01,1.03]	<0.0001***
PD-L1 inhibitor use	1.2[0.4,4.0]	0.192
Total PD-1 inhibitor duration, days	1.000[0.998,1.001]	0.234
Sodium, mmol/L	0.995[0.92,1.1]	0.635
Triglyceride, mmol/L	0.9[0.7,1.1]	0.215

Table 4. Comparisons of hospitalization characteristics before and after PD1/PD-L1 treatment in patients with new onsets heart failure, acute myocardial infarction, atrial fibrillation, and atrial flutter

Hospitalization characteristics before treatment	Before treatment Median (IQR);Max;N	After treatment Median (IQR);Max;N	P value
Heart failure (N=244)			
Average readmission interval, days	69.15(19.38-260.85);5669.0;n=203	23.7(14.1-39.4);1045.7;n=236	<0.0001* **
Total number of hospitalizations	7.0(3.0-12.5);32.0;n=203	10.5(6.0-17.0);77.0;n=236	<0.0001* **
Total in-hospital length of stay, days	17.0(7.0-35.0);343.0;n=203	31.0(16.0-54.5);190.0;n=236	<0.0001* **
Acute myocardial infarction (N=32)			
Average readmission interval, days	150.8(41.125-437.75);5669.0;n=32	25.4(12.8-43.6);272.1;n=37	<0.0001* **
Total number of hospitalizations	4.0(2.0-10.5);21.0;n=32	13.0(5.0-20.0);32.0;n=37	<0.0001* **
Total in-hospital length of stay, days	14.5(5.0-34.0);139.0;n=32	27.0(13.0-44.0);112.0;n=37	<0.0001* **
Atrial fibrillation (N=54)			
Average readmission interval, days	87.5(30.1-296.2);5669.0;n=46	31.9(16.9-49.9);290.7;n=54	<0.0001* **
Total number of hospitalizations	6.0(3.0-12.5);31.0;n=46	10.0(5.5-15.0);56.0;n=54	<0.0001* **
Total in-hospital length of stay, days	15.5(6.0-45.0);117.0;n=46	26.0(12.0-54.0);241.0;n=54	<0.0001* **
Atrial flutter (N=6)			
Average readmission interval, days	205.2(16.0-354.8);369.0;n=5	22.4(14.6-39.7);134.02;n=6	<0.0001* **
Total number of hospitalizations	3.0(3.0-6.0);6.0;n=5	7.5(7.0-12.5);25.0;n=6	<0.0001* **
Total in-hospital length of stay, days	22.0(5.0-30.0);82.0;n=5	30.0(21.5-39.5);70.0;n=6	<0.0001* **




Figure 1. Study flow diagram describing derivation of the study cohort.




Figure 2. Kaplan-Meier survival curve of new onset cardiac complications in cancer patients receiving PD-1 or PD-L1 inhibitors